MET and Holt-Oram syndrome: Notably, the inhibitor of ERK (U0126) attenuated the MET expression and migration in U2OS cells with or without LCN2 knockdown and the activator of ERK (tBHQ) promoted the MET expression and migration in HOS cells with or without LCN2 overexpression.